The clinical utility of ANA-Elia in connective tissue disease diagnosis in comparison to ANA-immunofluorescence

2018 ◽  
Author(s):  
Omar Alsaed
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Clinical Utility ◽  
Disease Diagnosis

scholarly journals Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study

2021 ◽  
Author(s):  
Shamma Ahmad Al Nokhatha ◽  
Eman Alfares ◽  
Luke Corcoran ◽  
Niall Conlon ◽  
Richard Conway
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Clinical Features ◽  
Clinical Utility ◽  
Clinical Symptoms ◽  
Final Diagnosis ◽  
Inflammatory Myopathies ◽  
Inclusion Criteria ◽  
Positive Group ◽  
Positive Results

AbstractMyositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are a feature of the idiopathic inflammatory myopathies (IIM), but are also seen in other rheumatic diseases, and in individuals with no clinical symptoms. The aim of this study was to assess the clinical utility of MSA and MAA and in particular the clinical relevance of weakly positive results. We included all patients at our institution who had at least one positive result on the Immunoblot EUROLINE myositis panel over a 6-year period (2015–2020). Associations with clinical features and final diagnosis were evaluated. Eighty-seven of 225 (39%) myositis panel tests met the inclusion criteria. There were 52 strong positives and 35 weak positives for one or more MSA/MAAs. Among the strong positive group, 15% (8/52) were diagnosed with IIM, 34.6% (18/52) with interstitial lung disease, 7.7% (4/52) with anti-synthetase syndrome, 25% (13/52) with connective tissue disease, and others accounted for 25% (13/52). In weak-positive cases, only 14% (5/35) had connective tissue disease and none had IIM. 60% (21/35) of weak-positive cases were not associated with a specific rheumatic disease. A significant number of positive myositis panel results, particularly weak positives, are not associated with IIM or CTD.

Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells

2015 ◽  
Vol 0 (0) ◽  
Author(s):  
Christoph Robier ◽  
Omid Amouzadeh-Ghadikolai ◽  
Mariana Stettin ◽  
Gerhard Reicht
Keyword(s):  
Connective Tissue ◽  
Sjögren’S Syndrome ◽  
Connective Tissue Disease ◽  
Indirect Immunofluorescence ◽  
Lupus Erythematosus ◽  
Clinical Utility ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Sjögren‘S Syndrome

AbstractWe compared the Elia CTD Screen (ECS), a fluoroenzymeimmunoassay incorporating 17 human antinuclear antigens (ANA), with indirect immunofluorescence (IIF) on Hep-2 cells in order to determine the clinical utility of the ECS in additon to or without IIF.We examined 1708 consecutive serum samples submitted for ANA testing using the ECS and IIF in parallel. Positive screen results were further examined by quantitative fluoroenzymeimmunoassays and/or immunoblots for antibody identification. The medical records were evaluated for systemic rheumatic disorders.Concordance between ECS and IIF was observed in 1344 (78.8%) samples. ECS had a better detection rate for anti-dsDNA, -SSA/Ro, -SSB/La, -U1RNP and -Jo-1 antibodies, whereas IIF was superior in the detection of anti-CENP-B antibodies as well as anti-histone, -nucleosome and -Pl-12 antibodies, which are not included in the ECS antigen panel. ECS had a 100% sensitivity for Sjögren’s syndrome, systemic sclerosis and Sharp syndrome. The sensitivity for Sjögren’s syndrome was slightly higher for ESC than for IIF (94%). IIF had a higher diagnostic sensitivity for systemic lupus erythematosus, indeterminated connective tissue disease, Raynaud’s syndrome and limited scleroderma, compared to ESC (100% vs. 80%, 100 vs. 75%, 89 vs. 57%, 100 vs. 88.9%).Our results suggest that the ECS represents an appropriate diagnostic tool for ANA screening. However, since some antigens are not incorporated in the ECS panel, and some ANA can also be missed by IIF, sequential or parallel screening with ECS and IIF may be reasonable when the clinical suspicion for connective tissue disease is high.

scholarly journals Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Mislav Radić ◽  
Rebecca S. Overbury
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Mixed Connective Tissue Disease ◽  
Raynaud’S Phenomenon ◽  
Disease Onset ◽  
Disease Diagnosis ◽  
Raynaud's Phenomenon ◽  
Classification Criteria ◽  
Case Presentation ◽  
Small Nuclear Ribonucleoprotein

Abstract Background The concept of mixed connective tissue disease (MCTD) as a unique connective tissue disease has endured for half a century. Disease onset can be in adulthood (MCTD) or of juvenile onset (jMCTD) and is characterized by overlapping features of systemic lupus erythematosus (SLE), polymyositis or dermatomyositis (PM/DM) and systemic sclerosis (SSc). No universally accepted classification criteria for MCTD exists, however agreed upon overlapping disease features include the presence of high titers of U1 small nuclear ribonucleoprotein particle antibodies (U1snRNP) in the peripheral blood, Raynaud’s phenomenon, synovitis, myositis and swollen hands or fingers. Characteristic capillaroscopy findings are commonly seen in MCTD and jMCTD, which may represent a crucial and key clue for classification as well as prognosis in these patients. Case presentation We present a young male patient, with symptom onset as early as age 13, who was diagnosed with MCTD at age 16 and found to have high titers of anti-U1snRNP antibodies, Raynaud’s phenomenon, synovitis, and swollen hands and fingers. Most interestingly, his video capillaroscopy at diagnosis was abnormal and revealed an active SSc-like pattern. His presentation and course are described. Conclusions We conclude that based on existing data, and as highlighted by this case presentation, nailfold video capillaroscopy should be included as an early screening tool for the detection of microangiopathy in patients with the diagnosis MCTD and jMCTD. Additionally, given its prevalence in this population at disease diagnosis, we recommend consideration be given to nailfold video capillaroscopy as a potentially important classification criteria and prognostic tool for jMCTD and MCTD.

scholarly journals FRI0583 Clinical utility of ana-elia vs ana-immunofluorescence in connective tissue disease

2018 ◽  
Author(s):  
O. Alsaed ◽  
L. Alamilah ◽  
O. Al-Radideh ◽  
M. Elkhalifa ◽  
A.-W. Al-Allaf
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Clinical Utility
Sign in / Sign up

Export Citation Format

Share Document